B-cell Antigen Receptor (BCR) Stimulation (Human Cells)

We use AHI1601 and AHI1301 goat F(ab’)2 fragments against human IgM and IgG.  Low levels of H2O2 (reversible, endogenous) or pervanadate (irreversible) can be used to dramatically enhance BCR signaling when added with or following BCR engagement.

A detailed phospho-flow protocol including BCR stimulation is available on the Irish lab website.

References:

B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Irish JM, Myklebust JH, Alizadeh AA, Houot R, Sharman JP, Czerwinski DK, Nolan GP, Levy R. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):12747-54. Epub 2010 Jun 11.

Notes: This study compared BCR signaling with follicular lymphoma (FL) patient clinical outcome and identified a new subpopulation of lymphoma cells termed Lymphoma Negative Prognostic (LNP) cells.  Presence of LNP cells at the time of diagnosis was closely and continuously associated with poor overall survival of FL patients.

Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. Irish JM, Czerwinski DK, Nolan GP, Levy R.  J Immunol. 2006 Aug 1;177(3):1581-9.

Notes: This study compared BCR signaling kinetics in mature and memory B cells from healthy human blood.

Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Irish JM, Czerwinski DK, Nolan GP, Levy R.  Blood. 2006 Nov 1;108(9):3135-42. Epub 2006 Jul 11.

Notes: This study compared BCR signaling kinetics in tumor and non-malignant B cells found within the same follicular lymphoma (FL) tumor.